JP5202789B2 - 子癇前症および子癇症患者におけるナトリウム/カリウムATPアーゼ活性を調整するためのジゴキシン免疫Fabの使用 - Google Patents
子癇前症および子癇症患者におけるナトリウム/カリウムATPアーゼ活性を調整するためのジゴキシン免疫Fabの使用 Download PDFInfo
- Publication number
- JP5202789B2 JP5202789B2 JP2004524798A JP2004524798A JP5202789B2 JP 5202789 B2 JP5202789 B2 JP 5202789B2 JP 2004524798 A JP2004524798 A JP 2004524798A JP 2004524798 A JP2004524798 A JP 2004524798A JP 5202789 B2 JP5202789 B2 JP 5202789B2
- Authority
- JP
- Japan
- Prior art keywords
- eclampsia
- sheep
- drug
- immune fab
- digoxin immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010034479 digoxin antibodies Fab fragments Proteins 0.000 title claims description 46
- 201000011461 pre-eclampsia Diseases 0.000 title claims description 38
- 239000011734 sodium Substances 0.000 title claims description 25
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims description 24
- 229910052708 sodium Inorganic materials 0.000 title claims description 24
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims description 19
- 208000002296 eclampsia Diseases 0.000 title claims description 19
- 239000011591 potassium Substances 0.000 title claims description 19
- 229910052700 potassium Inorganic materials 0.000 title claims description 19
- 108091006112 ATPases Proteins 0.000 title claims description 16
- 102000057290 Adenosine Triphosphatases Human genes 0.000 title claims description 16
- 230000000694 effects Effects 0.000 title claims description 12
- 241001494479 Pecora Species 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 20
- 229960005156 digoxin Drugs 0.000 claims description 15
- 238000001990 intravenous administration Methods 0.000 claims description 14
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 12
- 206010047139 Vasoconstriction Diseases 0.000 claims description 12
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 12
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- 230000025033 vasoconstriction Effects 0.000 claims description 11
- 230000010016 myocardial function Effects 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 230000006866 deterioration Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 description 16
- 230000035935 pregnancy Effects 0.000 description 14
- 210000002826 placenta Anatomy 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 9
- 210000001644 umbilical artery Anatomy 0.000 description 8
- 229940021344 digifab Drugs 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 229960000648 digitoxin Drugs 0.000 description 5
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010070863 Toxicity to various agents Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003671 Atrioventricular Block Diseases 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 208000010271 Heart Block Diseases 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- 206010040741 Sinus bradycardia Diseases 0.000 description 3
- 206010047163 Vasospasm Diseases 0.000 description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- 206010047302 ventricular tachycardia Diseases 0.000 description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 208000011318 facial edema Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 208000030941 fetal growth restriction Diseases 0.000 description 2
- 210000002458 fetal heart Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000036266 weeks of gestation Effects 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010005177 Blindness cortical Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019707 Hepatic rupture Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036451 Potassium imbalance Diseases 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010041273 Sodium imbalance Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710195583 Urinary protein 2 Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 208000009153 cortical blindness Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000021264 digitalis poisoning Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 201000011460 mild pre-eclampsia Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000005608 severe pre-eclampsia Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Description
Claims (29)
- 血管内容積縮小、血管収縮および心筋機能悪化を含む群のうちの少なくとも1つの子癇前症/子癇症の症状を逆転させるために、子癇前症/子癇症の症状を示すヒト患者に投与するための、ジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、3.0〜5.0ng/mL×患者体重(キログラム)÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与されるように用いられる、薬剤。
- 前記式における3.0〜5.0ng/mLを、4.0ng/mLとする、請求項1に記載の薬剤。
- 前記ジゴキシン免疫Fab(ヒツジ)が静脈内ボーラスで投与され、かつ、前記ジゴキシン免疫Fab(ヒツジ)の投与が固定スケジュールに基づき繰り返される、請求項1に記載の薬剤。
- 前記固定スケジュールが5〜8時間ごとである、請求項3に記載の薬剤。
- 前記固定スケジュールが6時間ごとである、請求項3に記載の薬剤。
- 子癇前症の症状を示すヒト患者における、ナトリウム/カリウムATPアーゼ活性を調整するためのジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、3.0〜5.0ng/mL×患者体重÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与されるように用いられる、薬剤。
- 前記式における3.0〜5.0ng/mLを、4.0ng/mLとする、請求項6に記載の薬剤。
- 前記薬剤が静脈内ボーラスで投与され、かつ、前記薬剤の投与が固定スケジュールに基づき繰り返される、請求項6に記載の薬剤。
- 前記固定スケジュールが5〜8時間ごとである、請求項8に記載の薬剤。
- 前記固定スケジュールが6時間ごとである、請求項8に記載の薬剤。
- 子癇前症/子癇症の症状を示すヒト患者において内因性ジギタリス様因子とレセプター部位との結合を防止するためのジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、3.0〜5.0ng/mL×患者体重÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与されるように用いられる、薬剤。
- 前記レセプター部位がナトリウム/カリウムATPアーゼである、請求項11に記載の薬剤。
- 前記式における3.0〜5.0ng/mLを、4.0ng/mLとする、請求項11に記載の薬剤。
- 前記薬剤が静脈内ボーラスで投与され、かつ、前記薬剤の投与が固定スケジュールに基づき繰り返される、請求項11に記載の薬剤。
- 前記固定スケジュールが5〜8時間ごとである、請求項14に記載の薬剤。
- 前記固定スケジュールが6時間ごとである、請求項14に記載の薬剤。
- ヒト患者における子癇前症/子癇症を抑制するためのジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、3.0〜5.0ng/mL×患者体重÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与されるように用いられる、薬剤。
- ジゴキシン免疫Fab(ヒツジ)の適切な投与量を計算する工程と、
前記投与量のジゴキシン免疫Fab(ヒツジ)を静脈内ボーラスで投与する工程と、
前記投与量のジゴキシン免疫Fab(ヒツジ)の静脈内ボーラスでの投与を固定スケジュールに基づき繰り返す工程と、を含むヒト患者における子癇前症および子癇症の抑制のためのジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、
前記ジゴキシン免疫Fab(ヒツジ)の適切な投与量を計算する工程が、患者の体重と、仮定の内因性ジギタリス様因子レベルとに基づいて行われ、
前記仮定の内因性ジギタリス様因子レベルが3.0〜5.0ng/mLである、薬剤。 - 仮定の内因性ジギタリス様因子レベルが4.0ng/mLである、請求項18に記載の薬剤。
- 前記ジゴキシン免疫Fab(ヒツジ)の適切な投与量を計算する工程が、
仮定の内因性ジギタリス様因子レベル×患者体重÷100という式を利用することを含む、請求項18に記載の薬剤。 - 前記固定スケジュールが5〜8時間ごとである、請求項18に記載の薬剤。
- 前記固定スケジュールが6時間ごとである、請求項21に記載の薬剤。
- 適切な投薬量のコルチコステロイドを投与する工程をさらに含む、請求項18に記載の薬剤。
- ヒト患者における子癇前症および子癇症を抑制するためのジゴキシン免疫Fab(ヒツジ)を含む薬剤であって、
仮定の内因性ジギタリス様因子レベル×患者体重÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与されるように用いられ、前記仮定の内因性ジギタリス様因子レベルが3.0〜5.0ng/mLである、薬剤。 - 前記仮定の内因性ジギタリス様因子レベルが4.0ng/mLである、請求項24に記載の薬剤。
- 前記薬剤が静脈内ボーラスで投与され、固定スケジュールに基づき繰り返して投与される、請求項24に記載の薬剤。
- 前記固定スケジュールが5〜8時間ごとである、請求項26に記載の薬剤。
- 前記固定スケジュールが6時間ごとである、請求項27に記載の薬剤。
- 血管内容積縮小、血管収縮および心筋機能悪化を含む群のうちの少なくとも1つの子癇前症/子癇症の症状を逆転させるために子癇前症/子癇症の症状を示すヒト患者にジゴキシン免疫Fab(ヒツジ)を投与することによって前記患者を治療するための薬剤の製造のためのジゴキシン免疫Fab(ヒツジ)の使用であって、3.0〜5.0ng/mL×患者体重(キログラム)÷100という式に従って前記ジゴキシン免疫Fab(ヒツジ)が投与される、使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/202,957 US7402313B2 (en) | 2002-07-25 | 2002-07-25 | Method for controlling preeclampsia and eclampsia |
US10/202,957 | 2002-07-25 | ||
US10/292,338 | 2002-11-12 | ||
US10/292,338 US20040018202A1 (en) | 2002-07-25 | 2002-11-12 | Use of digoxin immune Fab (ovine) for the regulation of sodium/potassium ATPase activity in preeclamptic and eclamptic patients |
PCT/US2003/023235 WO2004011028A1 (en) | 2002-07-25 | 2003-07-24 | Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005537284A JP2005537284A (ja) | 2005-12-08 |
JP5202789B2 true JP5202789B2 (ja) | 2013-06-05 |
Family
ID=31190675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004524798A Expired - Fee Related JP5202789B2 (ja) | 2002-07-25 | 2003-07-24 | 子癇前症および子癇症患者におけるナトリウム/カリウムATPアーゼ活性を調整するためのジゴキシン免疫Fabの使用 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1519746B1 (ja) |
JP (1) | JP5202789B2 (ja) |
AU (1) | AU2003254159B2 (ja) |
CA (1) | CA2492858C (ja) |
MX (1) | MXPA05001053A (ja) |
NO (1) | NO335545B1 (ja) |
WO (1) | WO2004011028A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
WO2007037788A1 (en) * | 2005-05-17 | 2007-04-05 | Charles David Adair | Antibody composition and passive immunization against pregnancy-induced hypertension using antidigoxin antibody (digibind) |
WO2007002638A1 (en) | 2005-06-27 | 2007-01-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-marinobufagenin antibodies and methods for their use |
US20080003230A1 (en) | 2006-07-03 | 2008-01-03 | Adair Charles D | Composition for modulating the expression of cell adhesion molecules |
WO2012109243A2 (en) * | 2011-02-07 | 2012-08-16 | Yuping Wang | Method of treating intercellular barrier dysfunction |
CA2907394A1 (en) * | 2013-03-15 | 2014-09-18 | Velo Bio, Llc | Method for treating eclampsia and preeclampsia |
WO2019236590A1 (en) * | 2018-06-04 | 2019-12-12 | University Of Maryland, Baltimore | Methods for preventing acute kidney injury |
-
2003
- 2003-07-24 EP EP03771818A patent/EP1519746B1/en not_active Expired - Lifetime
- 2003-07-24 CA CA2492858A patent/CA2492858C/en not_active Expired - Lifetime
- 2003-07-24 WO PCT/US2003/023235 patent/WO2004011028A1/en active Application Filing
- 2003-07-24 JP JP2004524798A patent/JP5202789B2/ja not_active Expired - Fee Related
- 2003-07-24 MX MXPA05001053A patent/MXPA05001053A/es active IP Right Grant
- 2003-07-24 AU AU2003254159A patent/AU2003254159B2/en not_active Ceased
-
2005
- 2005-02-24 NO NO20051001A patent/NO335545B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2004011028A1 (en) | 2004-02-05 |
CA2492858A1 (en) | 2004-02-05 |
AU2003254159A1 (en) | 2004-02-16 |
NO335545B1 (no) | 2014-12-29 |
AU2003254159B2 (en) | 2009-09-24 |
MXPA05001053A (es) | 2005-10-05 |
NO20051001L (no) | 2005-04-12 |
EP1519746A1 (en) | 2005-04-06 |
CA2492858C (en) | 2018-12-18 |
EP1519746B1 (en) | 2009-07-15 |
JP2005537284A (ja) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scheres et al. | Everything the clinician needs to know about evidence-based anticoagulation in pregnancy | |
NO20140969L (no) | Anvendelse av digoksin immunt Fab for regulering av natrium/kalium-ATPase-aktivitet hos preklampsiske og eklampsiske pasienter | |
NO335545B1 (no) | Anvendelse av digoksin immunt Fab for fremstilling av et medikament for behandling av preklampsiske og eklampsiske pasienter | |
Awadalla et al. | Management of Liddle syndrome in pregnancy: a case report and literature review | |
Haddad et al. | LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trial | |
Rand et al. | Maternal cardiomyopathy of pregnancy causing stillbirth | |
Ni et al. | Clinical characteristics of early-onset pre-eclampsia in singleton versus multiple pregnancies | |
Littler et al. | Reduced pulmonary arterial compliance in hypertensive pregnancy | |
Ishikawa et al. | Early diagnosis of the cardiopulmonary collapse type of amniotic fluid embolism with obstetrical disseminated intravascular coagulation during elective cesarean section: a case report | |
Cabrera-Naranjo et al. | Extensive stroke associated with tranexamic acid therapy | |
Greenberg et al. | Acute liver failure at 26 weeks' gestation in a patient with sickle cell disease | |
مطهری نژاد et al. | New-Onset Systemic Lupus Erythematosus in a Pregnant Woman: A Case Report | |
Alimdjanovna | ETIOPATHOGENETIC MECHANISMS IN PRE-ECLAMPSIA | |
Motaharinezhad et al. | New-onset systemic lupus erythematosus in a pregnant woman: A case report | |
Sudarman | Peripartum Cardiomyopathy (PPCM): Case Report and Review of Literatures | |
Konkov et al. | The implementation of new algorithm of the management of severe pre-eclampsia (Clinical case report) | |
Suresh | A Comparative Clinical Trial of Oral Hydration Therapy and L Arginine for the Management of Very Preterm Preeclampsia | |
RU2623064C1 (ru) | Способ профилактики фетоплацентарной недостаточности у беременных с хронической болезнью почек | |
Zhao et al. | Septic Shock in Pregnancy Caused by Acute Chorioamnionitis: Diagnosis, Surgical Selection, and Hemodynamic Therapy | |
JP2000505819A (ja) | 製剤製品 | |
Gordis et al. | Rheumatic heart disease and pregnancy in adolescent rheumatic fever patients | |
Nasreen Shafieqa | A Study of Maternal Serum Cystatin C and Serum Creatinine levels in Preeclamptic and Normotensive Pregnancies: A Case Control study | |
RU2349261C1 (ru) | Способ диагностики и лечения нарушений водного баланса у беременных | |
Harwal | Comparative Study of Magnesium Sulphate Regimens–Pritchard Regimen and Dhaka Regimen in the Management of Antepartum Eclampsia | |
Kitzmiller et al. | Diabetic nephropathy and pregnancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110603 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110912 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130213 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5202789 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |